Novo Nordisk On Saturday, Diabetes Pills Rybelsus, who lived a new treatment for people living with diabetes and heart disease, said that he showed a new treatment of a deceased test.
The pill has lowered heart attacks and hitting the risk of cardiovascular, heart attacks and hitting patients with diabetics, or with a placebo with heart disease, or without a placebo with a placebox. Denmark presenter presented Rybelseus Rybelsus in the American College of American Cardiology in Chicago.
Novo Nordisk said in an interview with the global chief medical worker Stephen Wough, applied to expand the pills to reduce the risk of pills to reduce the risk of severe cardiovascular aggravation in the United States and EU.
Rybelsus is the novo Nordisk’s Blockbuster Diabetes Iniy, who was taken once a week, is a daily oral formation of ozempti. Both treatments and the company’s weekly weight loss injection contain the active ingredient semaglutide.
In March 2024, Wegovy won the United States’s agreement to leak the risk of large cardiovascular events in adults with cardiovascular disease and obese or overweight. However, the pill presented on Saturday shows that patients who hesitate to injiate such as those who are afraid of needles can be easily treated.
“We want to choose a drug,” said Gough CNBC, “said Gough CNBC,” said Gough CNBC, “said Gough CNBC,” said Gough CNBC, “said Gough CNBC,” said, “We want a medication that we do not want an injection, or a verbal drug.”
Information comes as the slut of other pharmacies, including other pharmacies Eli Lilly, Try to develop oral GLP-1s for diabetes, weight loss and other conditions like sleep apnea.
The phase three tests, both in the standard treatment regime, and more than 9,600 patients who have received a placebo on the standard treatment regime, both in four years. About half of all patients received medications called SGLT2 inhibitors, first of all, are used to lower blood sugar in adults with type 2 diabetes.
At the end of the trial, 12% of Rybelsus and 13.8% of plasmers, 13.8% of plasmers live in heart attack, heart attack or hitting. Rybelsusus represents a total risk of 14% among those who take.
Researchers said that according to the American Cardiology College, the injection and other popular drugs included in the two previous tests included in other popular drugs, he said. GLP-1S imitates certain intestinal hormones to lower the appetite and adjust blood sugar, but also has other effects as reducing inflammation.
Rybelsus helped reduce the risk of fatal heart attack compared to Placebo, which is a common reduction in the risk of judgmental cardiovascular aggravation. Pill also increased the risk of non-fatal strokes and increased by 7% compared to the placebo with 12% and cardiovascular death.
There was no serious difference between the renal function associated with the renal function among Rybelsus and Placebo groups. However, the court was “clear”, not the renal benefits of the trial of the trial, but to explore cardiovascular.
Ozempic has already been confirmed to treat chronic kidney diseases in diabetics.
Gastrointestinal problems such as the most commonly seen side effects, nausea, diarrhea and constipation, Rybelsus rarely had gastrointestinal problems. These symptoms correspond to the side effects of the injection of semaglutid.
Similar results are seen among people with different health conditions in all sub-groups of patients – age, gender and the court.
Unlike their injection colleagues, Rybelsus should be carried over a free stomach before breaking a small amount of water before breakfast. Despite these requirements, the work “could accept the medicine of patients as directed and can gain benefits of cardiovascular health,” he said.
